CSIMarket
 
Aadi Bioscience Inc   (AADI)
Other Ticker:  
 
 
Price: $2.1200 $-0.05 -2.304%
Day's High: $2.17 Week Perf: 9.28 %
Day's Low: $ 2.10 30 Day Perf: 11.58 %
Volume (M): 184 52 Wk High: $ 8.65
Volume (M$): $ 389 52 Wk Avg: $5.12
Open: $2.16 52 Wk Low: $1.55



 Market Capitalization (Millions $) 57
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 24
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) 24
 Capital Exp. (TTM) (Millions $) 4

Aadi Bioscience Inc
Aadi Bioscience Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. They specialize in designing small molecule drugs that aim to target cancer cells while minimizing harm to healthy cells. Aadi Bioscience Inc aims to provide safer and more effective treatment options for patients, with a focus on precision medicine and personalized oncology. They leverage cutting-edge research and technology to develop novel therapeutics and are committed to advancing the field of oncology to improve patient outcomes.


   Company Address: 17383 Sunset Boulevard Pacific Palisades 90272 CA
   Company Phone Number: 744-8055   Stock Exchange / Ticker: NASDAQ AADI
   AADI is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Aadi Bioscience Inc

Revenue Boost in Fiscal Fourth Quarter of 2023, But Profitability Remains Elusive

Exciting Growth Ahead: Aadi Bioscience Inc. Continues to Thrive in the Pharmaceutical Industry
LOS ANGELES, Feb. 26, 2024 - Aadi Bioscience Inc. (NASDAQ: AADI) has shown remarkable progress in the stock market, with their recent report indicating a surge in revenue by an impressive 21.025% to $6.33 million from the previous year. This staggering growth is a testament to their unwavering commitment to developing and commercializing precision therapies for patients with mTOR pathway alterations.
Despite a widening of losses, with losses per share at $-0.50, the company has managed to improve its earnings per share sequentially from $-0.60 per share. Furthermore, their revenue also saw a significant increase of 6.159% from $5.96 million. These figures clearly demonstrate Aadi Bioscience Inc.'s resilience and ability to adapt in a competitive market.

Aadi Bioscience Inc

Aadi Bioscience Inc Surges ahead with Impressive Financial Turnaround in Q3 2023

Aadi Bioscience Inc, a biotechnology company, recently released its financial results for the fiscal period of July to September 30, 2023. The company showcased significant improvements in its financial performance compared to the previous year.
During this fiscal period, Aadi Bioscience Inc reported a decrease in the loss per share, dropping from $-0.68 per share to $-0.60 per share. Additionally, the company's income per share also improved, going from $-0.67 per share in the prior reporting period to an undisclosed positive figure.

Aadi Bioscience Inc

Positive Momentum: Aadi Bioscience Inc Reveals Promising Financial Performance in Q2 2023

Aadi Bioscience Inc, a pharmaceutical company, has recently released their financial results for the second quarter of 2023. In this article, we will analyze these results and provide an interpretation of the facts.
Starting with the company's earnings per share (EPS), Aadi Bioscience Inc experienced a loss of $-0.67 per share in the second quarter of 2023. This is an improvement compared to the loss of $-0.87 per share in the same quarter last year. However, the loss increased compared to the preceding financial reporting period, where the company reported a loss of $-0.57 per share.

Aadi Bioscience Inc

Aadi Bioscience Inc Reports Massive Losses: $-0.57 per Share in Q1 2023

Aadi Bioscience Inc, a biopharmaceutical company that focuses on the development of innovative cancer treatments, has reported a cumulative net loss of $-62 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -42.51%. This indicates that the company has not been profitable during the period and has been operating at a loss.
Within the Major Pharmaceutical Preparations industry, 189 other companies had a higher return on equity than Aadi Bioscience Inc. This showcases that the company still has a long way to go before it can become profitable. The total ranking of Aadi Bioscience has also deteriorated compared to the previous quarter, going from 0 to 3303.






 

Aadi Bioscience Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Aadi Bioscience Inc does not provide revenue guidance.

Earnings Outlook
Aadi Bioscience Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com